Pfizer Voluntarily Recalls Children’s Advil Over Fears of Overdosing


Children’s Advil is used to temporarily reduce fever and relieve minor aches and pains due to the common cold, flu, sore throat, headaches or toothaches.

Here’s what you need to know about the recall.

Why was Children’s Advil recalled?

Pfizer recalled Children’s Advil due to a mix up on the dosage cup. Parents were reporting that the dosage cup provided measurements in teaspoons, even though the dosing directions were in milliliters. The packaging also did not give proper instructions on how to convert between teaspoons and milliliters. Pfizer was concerned that this discrepancy could result in overdosing.

The most common symptoms associated with an Advil overdose include nausea, vomiting, headache, drowsiness, blurred vision and dizziness.

Which products were recalled?

In this recall, only one lot was affected:

  • Drug: Children’s Advil Suspension Bubble Gum Flavor, 4 fl oz bottle (120 ml)
  • Manufacturer: Pfizer
  • Lot: R51129 (Expiration date: 11/2020)
  • National Drug Code (NDC): 0573-0207-30

According to an FDA announcement, the product was distributed nationwide in the United States from May to June 2018.

What do I do if I think I have a recalled product?

Pfizer has notified wholesalers, distributors and retailers to arrange for return of all recalled products, and affected lots should be removed from pharmacy shelves soon.

If you have questions regarding this recall, you can reach the Pfizer Consumer Healthcare Information Line at 1-800-88-ADVIL, Monday through Friday from 9AM to 5PM Eastern Standard Time. If you think your child has experienced any side effects related to the recall, contact their healthcare provider for further instructions.

Be sure to always inspect your medications, including all parts of the packaging and devices. If you ever notice your medication doesn’t look or smell right, contact the manufacturer or ask your pharmacist for more information. Any adverse reactions or quality problems can also be reported to the FDA’s MedWatch Reporting Program as they can conduct further investigations.

Source: Read Full Article